The EU Commission will receive 30 million doses of the vaccine developed by Valneva against the new type of coronavirus, and will have the opportunity to receive 30 million doses.
It is stated that Valneva’s vaccine will contain an inactive virus, and Phase 3 studies of the vaccine have not started yet.
Details of vaccine distribution process clarified
The EU Commission is holding vaccine purchasing negotiations and agreements on behalf of member countries. Until today, contracts have been signed with 6 companies for approximately 2.3 billion doses of vaccine.restbet Um sich anzumelden, müssen Sie die erneuerte Adresse der Plattform verwenden.
restbet499 hat eine neue Login-Adresse und jetzt müssen Sie diese Adresse verwenden.
The Union, previously including options, to receive 600 million doses of vaccine with BioNTech-Pfizer, 400 million with AstraZeneca, 300 million with Sanofi-GSK, 400 million with Johnson and Johnson company, 405 million with CureVac, 160 million with Moderna. had made a contract.
AB’s preliminary negotiations with Novavax company other than Valneva on vaccination purchase were completed.